2,5and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators

Details for Australian Patent Application No. 2004216813 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Putman, David George

Agent Spruson & Ferguson

Pub. Number AU-B-2004216813

PCT Pub. Number WO2004/078176

Priority 60/451,516 03.03.03 US

Filing date 23 February 2004

Wipo publication date 16 September 2004

Acceptance publication date 11 September 2008

International Classifications

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 217/08 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 217/24 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

8 September 2005 PCT application entered the National Phase

  PCT publication WO2004/078176 Priority application(s): WO2004/078176

11 September 2008 Application Accepted

  Published as AU-B-2004216813

22 January 2009 Standard Patent Sealed

15 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004216823-Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of IP-10 mediated diseases

2004216795-Identifying related information given content and/or presenting related information in association with content-related advertisements